Cleared Traditional

MICRON-SCOPE II (K926412) - FDA 510(k) Clearance

Class I Ophthalmic device.

K926412 · Chiron Vision Corp. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1994
Decision
575d
Days
Class 1
Risk

K926412 is an FDA 510(k) clearance for the MICRON-SCOPE II. Classified as Drum, Eye Knife Test (product code HMS), Class I - General Controls.

Submitted by Chiron Vision Corp. (Irvine, US). The FDA issued a Cleared decision on July 19, 1994 after a review of 575 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4230 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Ophthalmic submissions.

View all Chiron Vision Corp. devices

Submission Details

510(k) Number K926412 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 21, 1992
Decision Date July 19, 1994
Days to Decision 575 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
465d slower than avg
Panel avg: 110d · This submission: 575d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HMS Drum, Eye Knife Test
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.4230
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.